Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $61.9652W HIGH $150.44
Volume
679.89 K
Value Traded
87.02 M
Short % Float
10.95%
-9.46%Week
-3.34%1 Month
-25.18%3 Month
+16.06%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.52 B
EPS (TTM)
0.80
P/E Ratio
119.81
Ent. Value
4.06 B
Total Shares
47.19 M
Float Shares
23.97 M
Insiders
49.20%
Institutions
28.88%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BLLN Catalyst Timeline
Dated clinical, regulatory and corporate events for BillionToOne, Inc. Class A Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for BillionToOne, Inc. Class A Common Stock
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
▲PublicationPresentation
Publication of study showing Northstar Response predicts immunotherapy outcomes better than imaging
advanced solid tumors receiving immunotherapysource ↗
Past FDA Catalysts and PDUFA Decisions
How BLLN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
BillionToOne, Inc. Class A is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BLLN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tsao DavidDirector, Officer (Chief Technology Officer) | Option | 10,000 11,000 held | $2.80 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BLLN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.2 % (100 %) | 10.41 M | 86.81 K | -5.45% ( -5.00 K) |
BLLN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BLLN ranks across every disease it competes in
Competitive Position is a premium feature
See how BLLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBLLN News
-BLLN
Oct 7, 2026▼ -4.2%today
BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
BillionToOne's Northstar Response assay has been shown to effectively monitor cancer treatment responses in a peer-reviewed study. The study compared it with a tumor-informed ctDNA assay, demonstrating comparable or superior results without needing tissue samples. This advancement could significantly benefit patients by providing timely and accurate monitoring of disease progression.
Read more →-BLLN
Sep 2, 2026BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
BillionToOne, Inc. will participate in the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The company's management will engage in a fireside chat, highlighting their advancements in molecular diagnostics. A live webcast will be available for interested parties. This participation reflects the company's commitment to innovation in healthcare.
Read more →-BLLN
Sep 1, 2026BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
BillionToOne has launched Northstar Origin, a new liquid biopsy test that predicts tissue of origin from circulating cell-free DNA, aimed at patients with cancer of unknown primary. The test enhances diagnostic accuracy and reduces the need for additional tissue samples. Additionally, the Northstar Select panel has been expanded to include 102 genes, improving its sensitivity and clinical utility.
Read more →-BLLN
Aug 18, 2026Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
BillionToOne, Inc. announced the publication of a significant study demonstrating the efficacy of its cfDNA fetal risk assessment in general-risk pregnancies. The study, involving over 2,200 pregnant carriers, showed high sensitivity and specificity, suggesting that this method could enhance routine prenatal screening. The findings support the integration of cfDNA testing into standard care, potentially improving outcomes for affected children.
Read more →-BLLN
Aug 5, 2026▼ -38.9%on this news
BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
BillionToOne, Inc. reported a strong financial performance for Q2 2026, with total revenue reaching $109.4 million, a 64% increase from the previous year. The company reiterated its revenue guidance for the full year, expecting between $450 million to $465 million. Key operational highlights include the upcoming launch of an expanded fetal risk screening panel and an add-on feature for its Northstar Select test.
Read more →-BLLN
Jul 20, 2026BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar
BillionToOne has appointed Dr. Ethan Dmitrovsky as Chief Medical Officer for Oncology, aiming to enhance its Northstar liquid biopsy portfolio. Dr. Dmitrovsky, a prominent figure in cancer research, will focus on expanding clinical adoption and guiding treatment decisions for patients with solid tumors. His leadership is expected to drive growth and innovation within the company.
Read more →-BLLN
Jul 15, 2026BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
BillionToOne, Inc. (NASDAQ: BLLN) will announce its second quarter financial results for 2026 on August 5, 2026, after market close. A conference call is scheduled for the same day at 1:30 PM PT to discuss these results. The company is known for its innovative molecular diagnostics technology.
Read more →-BLLN
Jun 29, 2026BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
BillionToOne's Northstar Response assay has been shown to be a more effective predictor of survival for cancer patients undergoing immunotherapy compared to standard imaging methods. In a peer-reviewed study involving 142 patients across various tumor types, it was found that combining molecular monitoring with imaging significantly enhances predictive accuracy. The assay allows for earlier detection of disease progression, potentially improving patient management.
Read more →-BLLN
May 27, 2026▲ +7.7%on this news
BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
BillionToOne, Inc. will participate in the William Blair 46th Annual Growth Stock Conference on June 2, 2026. Management is scheduled to present from 12:40 PM to 1:10 PM Central Time. The event will feature a live and archived webcast available on the company's investor relations website.
Read more →-BLLN
May 6, 2026BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
BillionToOne, Inc. reported strong financial results for Q1 2026, with total revenue reaching $108.4 million, an 84% increase from the previous year. The company also launched a new prenatal testing assay, Unity ConfirmTM, and raised its full-year revenue guidance to between $450 million and $465 million. The significant growth reflects the company's expanding market presence and product offerings.
Read more →-BLLN
Apr 15, 2026BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026
BillionToOne, Inc. will announce its financial results for Q1 2026 on May 6, 2026. The results will be shared after market close, followed by a conference call at 1:30 PM PT. Analysts are encouraged to register in advance for the call, which will also be available via a live and archived webcast.
Read more →-BLLN
Mar 5, 2026▼ -10.7%on this news
BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance
BillionToOne, Inc. reported impressive financial results for Q4 and full year 2025, showcasing a 113% revenue increase in Q4 compared to the previous year. The company also raised its revenue guidance for 2026, projecting growth of 41% to 46%. With strong performance in prenatal and oncology testing, BillionToOne is optimistic about its future prospects.
Read more →-BLLN
Feb 17, 2026▲ +5.2%on this news
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
BillionToOne, Inc. has announced it will release its financial results for the fourth quarter and full year of 2025 on March 4, 2026. The results will be shared after market close, followed by a conference call at 1:30 PM PT. This event highlights the company's commitment to transparency and investor communication.
Read more →-BLLN
Feb 10, 2026BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal Care
BillionToOne has launched the UNITY expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, enhancing prenatal care for conditions like Hemolytic Disease of the Fetus and Newborn (HDFN) and Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). These non-invasive tests provide early and accurate fetal antigen status, significantly improving clinical decision-making. The new offerings are expected to reshape standards of care in affected pregnancies.
Read more →-BLLN
Dec 24, 2025BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference
BillionToOne, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. Management will present from 9:45am to 10:25am Pacific Time. A live and archived webcast will be available on their investor relations website. The company aims to provide powerful and accurate molecular diagnostics.
Read more →About BillionToOne, Inc. Class A Common Stock
Headquarters1035 O'BRIEN DRIVE, MENLO PARK, CA
BIOPHARMAWATCH ELITE PLUS
Trade the next BLLN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime